Antera Therapeutics

Antera Therapeutics is a privately held biotechnology company based in Boston, Massachusetts that was founded in 2014 by Clarence Friedman and Jacob Stahl.

The company aims to prevent the development of allergies in infants. Its first product, Aralyte, is meant to help parents introduce peanuts into an infant's diet in a structured and convenient way and avoid the development of peanut allergies.

Aralyte is a special dietary use regimen that incorporates the findings from the LEAP (Learning Early About Peanut Allergy) Clinical Program. The liquid formula contains the precise protein amounts used in the study and contains full doses of vitamins, such as Vitamin D, allowing it to be given in combination with breastfeeding or formula.

In November 2016, the FDA's Office of Compliance in Biologics Quality in the Center for Biologics Evaluation and Research (CBER) had sent a letter to Anterra because of its selling an unapproved biologic intended to prevent a peanut allergy. As the product appeared to be a drug, the FDA stated that the product was not the subject of an approved biologics license application (BLA) nor was there an IND in effect for the use of the product.

On November 1, 2016 Antera Therapeutics received a grant from MassChallenge.

On June 1, 2016 Antera Therapeutics completed their seed funding round with $1.7 million in funding RA Capital and undisclosed investors.

On June 19, 2015 Antera Therapeutics borrowed $265,000 in the form of debt financing.